Interim data show Duravyu improves BCVA, central subfield thickness in DME
Click Here to Manage Email Alerts
EyePoint Pharmaceuticals has announced positive 16-week data from the ongoing phase 2 VERONA trial evaluating Duravyu for patients with diabetic macular edema, according to a press release.
“DME is a prevalent disease with a significant need for more durable treatments,” Jay S. Duker, MD, EyePoint’s president and CEO, said in the release. “The interim data from the VERONA trial demonstrates that after a single Duravyu 2.7 mg treatment there was a meaningful, early and maintained improvement in BCVA paired with strong anatomical improvement in retinal thickness, demonstrating the potential for Duravyu in DME as a sustained delivery therapy.”
According to the release, all 27 patients completed the 16-week visit, at which best corrected visual acuity improved + 8.9 letters in the Duravyu 2.7 mg group compared with + 3.2 letters in the aflibercept control group. In addition, central subfield thickness improved by 68.1 microns vs. 30.5 microns, respectively, and 82% vs. 50% of eyes were free of supplements. The company also reported visual and anatomical gains as early as week 4.
Further, among patients who have reached the trial’s 24-week visit, continued positive trends in BCVA and anatomy have been observed, with no Duravyu-related ocular or systemic serious adverse events reported.
Duravyu (formerly EYP-1901) is an intravitreal insert that delivers vorolanib, a tyrosine kinase inhibitor.
“Reducing the treatment burden in patients with DME is a critical unmet need,” Adam Gerstenblith, MD, a principal investigator in the trial and vitreoretinal surgeon at Mid Atlantic Retina Specialists, said in the release. “As a clinician dedicated to advancing retinal care, I am encouraged by the interim clinical data demonstrating the potential for Duravyu 2.7 mg to extend treatment intervals while improving vision without sacrificing anatomy.”
Read more about
Click Here to Manage Email Alerts